MedTrace Logo

Effect of Oral Adenosine-triphosphate (ATP) on Human Muscle Performance

NCT01141504 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2012-01-10

No results posted yet for this study

Summary

Adenosine-triphosphate (ATP) serves as the sole energy source for muscle contraction. Therefore human performance of brief maximal exercise is limited, in part, by the availability of ATP to the contracting muscle. Because muscle ATP storage is small (enough to sustain maximal exercise for less than 1 second), factors that enhance either storage or resynthesis of ATP may have a positive impact on repeated muscle contractions. The current study will test the hypothesis that increasing ATP availability to muscle via oral supplementation will improve performance of repeated high intensity exercise as measured by a) work performed in each of the three 50 contraction fatigue tests, b) sum of total work performed, and c) percentage decrement in total work from the first to third third 50 contraction test.

Conditions

  • Healthy Subjects

Interventions

DIETARY_SUPPLEMENT

PeakATP 250

The nutritional intervention provides for oral ingestion of 250 mg PeakATP per day

DIETARY_SUPPLEMENT

Placebo

Placebo capsules that are comparable in size and color to the active comparator for blinding purposes

DIETARY_SUPPLEMENT

PeakATP 400

The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day

DIETARY_SUPPLEMENT

PeakATP 400 plus proprietary blend

The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day plus a proprietary blend of additional nutrients

Sponsors & Collaborators

  • Iowa State University

    collaborator OTHER

  • Metabolic Technologies Inc.

    lead INDUSTRY

Principal Investigators

  • John A Rathmacher, PhD · Metabolic Technologies Inc.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01141504 on ClinicalTrials.gov